|Access to this symposium is free, but you must first be a
registered FREE ZONE user of HDCN. If not already an HDCN FREE ZONE user, please
register at this link and select a username and password.
| After participating in this program, the learner should be able to:
- Understand how maintenance iron protocols affect anemia outcomes and total iron dose.
- To be able to identify clinical and laboratory stop points for iron therapy.
- Understand how available iron agents differ in preparation, pharmacokinetics, dosing, and evidence of safety.
- Understand how improving anemia in patients with CKD affects cardiac and functional status.
David Van Wyck, MD
Professor of Medicine and Surgery
The University of Arizona
College of Medicine
Sheryl Salvato, RN
National Nephrology Associates
Donald Silverberg, MD
Department of Nephrology
Tel Aviv Medical Center
Tel Aviv, Isreal
This satellite symposium is sponsored by an unrestricted educational grant from American Regent Laboratories, Inc. This activity has been planned and produced in accordance with CE
guidelines and policies. From a CE symposium held on May 23, 2002 at the American Nephrology Nurses' Association (ANNA) Annual Meeting in Orlando, FL. This symposium was approved by ANNA. It was not part of the official ANNA Annual Meeting.
This activity has been awarded 1.5 contact hours by the American Nephrology Nurses Association (ANNA) which is accredited as a provider and approver of continuing education in nursing by the American Nurses Credentialing Center-Commission on Accreditation (ANCC-COA).
Posting Date: October 2002
CE Credit Eligible
CE Credit Hours/Completion Time: 1.5
Target Audiences: Nurses, nurse practitioners, and other healthcare professionals who treat and manage patients with CKD.
Method of participation: Listen to the talk, read the PubMed
abstracts linked to data slides and talk references, take the post-test, read
the linked abstracts in the post-test answer feedback material.
Chronic kidney disease affects 30-40 million Americans, of whom
several hundred thousand require renal replacement therapy. These
will allow nephrology nurses, pharmacists, and technicians to obtain
up-to-date information about issues related to care of renal patients.
This continuing education activity is based on an approved Satellite Symposium which took place at the American Nephrology Nurses' Association (ANNA) 2002 Annual Meeting, and is approved by ANNA,
East Holley Avenue, Box 56, Pitman, New Jersey 08071-0056, an accredited approver by the American Nurse Credentialing Center Commission on Accreditation (ANCC-COA). ANNA is an approved provider of CE
to nursing by the California Board of Registered Nursing, BRN Provider No. 00910, the Alabama Board of Nursing, BRN Provider No. PO324, and the Kansas State Board of Nursing, Provider No. LT0148-0738.
This course offering is applicable for RN and LPN licensure in Kansas. Licensees in the states of CA, AL, and KS must retain this certificate for four years after the CE activity is completed. Other
mandatory CE states may have different record keeping requirements. Please be aware of your state's procedure.
The activity provider is HDCN, 15W560 89th St., Hinsdale, IL 60527.
The American Nephrology Nurses' Association, as well as HDCN have conflict of
interest policies that require course faculty to disclose
any real or apparent commercial financial affiliations related to the
content of their presentations/materials. It is not assumed that these
financial interests or affiliations will have an adverse
impact on faculty presentations; they are simply noted here to fully inform
FACULTY DISCLOSURE STATEMENTS
Dr. Van Wyck is a member of the Speakers Bureau for American Regent Laboratories, Inc and Amgen Inc.
S. Salvato is a member of the Speakers Bureau for American Regent Laboratories, Inc
Dr. Silverberg is a member of the Speakers Bureau for American Regent Laboratories Inc, Amgen, and Johnson and Johnson.
educational activity may contain discussion of published
investigational uses of agents that are not indicated by
The American Nephrology Nurses' Association, and HDCN do not
recommend the use of any agent outside of the labeled
Please refer to the official prescribing information for
product for discussion of approved indications,
DISCLOSURE OF UNLABELED USE:
have an implied responsibility to use the newly acquired
to enhance patient outcomes and their own professional
The information presented in this activity is not meant
to serve as a guideline for patient management. Any procedures,
medications, or other courses of diagnosis or treatment
discussed or suggested in this activity should not be used by clinicians
without evaluation of their patient's conditions and possible
on dangers in use, review of any applicable manufacturer's product
information, and comparison with recommendations of other authorities.